Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1215612.RArDhNUkJoRzKrUI3F_lBvjh_iv4vqKQm68zfGn63eV8s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1215612.RArDhNUkJoRzKrUI3F_lBvjh_iv4vqKQm68zfGn63eV8s130_assertion type Assertion NP1215612.RArDhNUkJoRzKrUI3F_lBvjh_iv4vqKQm68zfGn63eV8s130_head.
- NP1215612.RArDhNUkJoRzKrUI3F_lBvjh_iv4vqKQm68zfGn63eV8s130_assertion description "[CXCL1-inhibting agents such as endostatin may constitute a useful approach to treat the malignant or intermediate vascular lesions.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1215612.RArDhNUkJoRzKrUI3F_lBvjh_iv4vqKQm68zfGn63eV8s130_provenance.
- NP1215612.RArDhNUkJoRzKrUI3F_lBvjh_iv4vqKQm68zfGn63eV8s130_assertion evidence source_evidence_literature NP1215612.RArDhNUkJoRzKrUI3F_lBvjh_iv4vqKQm68zfGn63eV8s130_provenance.
- NP1215612.RArDhNUkJoRzKrUI3F_lBvjh_iv4vqKQm68zfGn63eV8s130_assertion SIO_000772 25175281 NP1215612.RArDhNUkJoRzKrUI3F_lBvjh_iv4vqKQm68zfGn63eV8s130_provenance.
- NP1215612.RArDhNUkJoRzKrUI3F_lBvjh_iv4vqKQm68zfGn63eV8s130_assertion wasDerivedFrom befree-2016 NP1215612.RArDhNUkJoRzKrUI3F_lBvjh_iv4vqKQm68zfGn63eV8s130_provenance.
- NP1215612.RArDhNUkJoRzKrUI3F_lBvjh_iv4vqKQm68zfGn63eV8s130_assertion wasGeneratedBy ECO_0000203 NP1215612.RArDhNUkJoRzKrUI3F_lBvjh_iv4vqKQm68zfGn63eV8s130_provenance.